High-Dose ARBs May Benefit Diabetics
High doses of valsartan reduce albuminuria to a greater extent than the conventional 160 mg dose in type 2 diabetics, researchers concluded.
Chronic Kidney Disease
Novel Peptide-Based ESA Promising
BARCELONA—A novel peptide-based erythropoiesis-stimulating agent (ESA) called Hematide safely raises hemoglobin levels in anemic CKD patients and maintains stable hemoglobin levels in hemodialysis patients who switch to the drug from epoetin alfa, data suggest.
The Anemia Management Controversy
On September 11, 2007, an FDA panel of health experts declined to recommend the quasi-expected restrictions on the use of the erythropoietin stimulating agents (ESA) in CKD patients.
Once Monthly C.E.R.A. Found Beneficial
BARCELONA—Once-monthly dosing of continuous erythropoietin receptor activator (C.E.R.A.) maintains stable hemoglobin levels in CKD patients regardless of age, gender, or comorbidities, according to study data presented here at the 44th Congress of the European Renal Association-European Dialysis and Transplant Association.
CKD-Related Anemia Often Untreated
Only about one in 10 CKD-related outpatient visits for anemia management in the United States result in a prescription for an anemia medication, data show.
Antithrombotic Safety Linked to GFR
Fondaparinux may be safer than enoxaparin as treatment for non-ST-segment elevation acute coronary syndromes (ACS) in patients with renal dysfunction.
More Type 2 Diabetics Face ESRD
End-stage renal disease (ESRD) is affecting a growing proportion of type 2 diabetics in Australia and New Zealand, a study found.
Lowering Homocysteine Not Beneficial
Using high doses of folic acid and B vitamins to lower elevated homocysteine levels in patients with advanced CKD (ACKD) or end-stage renal disease (ESRD) does not improve survival or decrease the incidence of vascular disease, data show.
How to Manage Vitamin D Deficiency
The active forms of vitamin D—calcitriol, paricalcitol, and doxercalciferol—which also are known as vitamin D receptor activators (VDRAs), have been largely used in nephrology only as a treatment for secondary hyperparathyroidism, an elevation in parathyroid hormone (PTH) due to renal failure.
Untreated Anemia Increases Morbidity
CHICAGO—Diabetics with CKD whose anemia is untreated have twice the overall risk of CVD-related hospitalizations, according to data reported at the 67th Scientific Sessions of the American Diabetes Association.
- Loading...
Loading...
Loading... 
Loading...